Bank of Hawaii Trims Position in Johnson & Johnson (JNJ)
Bank of Hawaii cut its stake in Johnson & Johnson (NYSE:JNJ) by 1.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 104,176 shares of the company’s stock after selling 1,217 shares during the period. Johnson & Johnson comprises approximately 1.2% of Bank of Hawaii’s portfolio, making the stock its 15th largest position. Bank of Hawaii’s holdings in Johnson & Johnson were worth $13,781,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Harding Loevner LP acquired a new position in Johnson & Johnson in the second quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the period. Lenox Wealth Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after acquiring an additional 5 shares during the period. Shine Investment Advisory Services Inc. acquired a new position in shares of Johnson & Johnson during the second quarter worth about $177,000. Finally, Ullmann Financial Group Inc. acquired a new position in shares of Johnson & Johnson during the first quarter worth about $186,000. 65.90% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson (NYSE JNJ) opened at $140.59 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1 year low of $110.76 and a 1 year high of $144.35. The firm has a market cap of $376,139.66, a PE ratio of 19.61, a price-to-earnings-growth ratio of 2.85 and a beta of 0.80.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be given a dividend of $0.84 per share. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.39%. Johnson & Johnson’s payout ratio is currently 58.33%.
A number of research analysts have recently issued reports on the stock. J P Morgan Chase & Co boosted their price target on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 16th. Citigroup assumed coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They set a “neutral” rating and a $140.00 price target on the stock. Jefferies Group set a $145.00 price target on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Tuesday, August 15th. BMO Capital Markets reiterated a “positive” rating and set a $152.00 price target (up from $145.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Finally, Royal Bank Of Canada boosted their price target on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and an average target price of $144.59.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.